Celebrex-Derived Drug Targets Common Childhood Bone Tumor

Jiayuh Lin, PhD, and colleagues at Nationwide Children's Hospital have developed a drug to target the most common cancerous bone tumor in children, osteosarcoma, using a version of the FDA-approved drug, Celebrex. The team will soon begin testing the drug using human and canine tumor cell lines thanks to a two-year, $200,000 grant from Alex's Lemonade Stand Foundation for Childhood Cancer.

Read the whole article on Newswise - Scinews

More from Newswise - Scinews